PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JOSEPH COLLARD	09/20/2011
OLGA KHORKOVA SHERMAN	07/23/2012

RECEIVING PARTY DATA

Name:	CuRNA, Inc.
Street Address:	4400 BISCAYNE BOULEVARD
City:	MIAMI
State/Country:	FLORIDA
Postal Code:	33137

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	13575206
PCT Number:	US2011022304

CORRESPONDENCE DATA

Fax Number: 3055754140

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: patents@opko.com

Correspondent Name: OPKO Health, Inc.

Address Line 1: 4400 BISCAYNE BOULEVARD

Address Line 4: MIAMI, FLORIDA 33137

ATTORNEY DOCKET NUMBER: CURN00130

NAME OF SUBMITTER: Letitia Newbold

Total Attachments: 9

502076418

source=CURN00130_US_ASSIGNMENT#page1.tif source=CURN00130_US_ASSIGNMENT#page2.tif source=CURN00130_US_ASSIGNMENT#page3.tif

PATENT REEL: 029035 FRAME: 0425 135/5206

source=CURN00130_US_ASSIGNMENT#page4.tif source=CURN00130_US_ASSIGNMENT#page5.tif source=CURN00130_US_ASSIGNMENT#page6.tif source=CURN00130_US_ASSIGNMENT#page7.tif source=CURN00130_US_ASSIGNMENT#page8.tif source=CURN00130_US_ASSIGNMENT#page9.tif

PATENT ASSIGNMENT	Docket Number:	CURN00130	US

WHEREAS, the undersigned:

- 1. COLLARD, Joseph, 1004 Brooks Lane, Delray Beach, FL 33483
- 2. KHORKOVA SHERMAN, Olga, 18288 SE Heritage Drive, Tequesta, FL 33469

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

TREATMENT OF RNASE H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1

\boxtimes	for which a United States Patent Applica	tion No. <u>13/575,206</u>	filed on_July	y 25, 2012 ;
\boxtimes	for which Provisional Application Nos	61/297,878 filed on	January 25, 2010	_in the United
	Stated Patent Office;			
\boxtimes	for which International Application No	PCT/US2011/022304	filed on January 2	5, 2011 in the
	U.S. Receiving Office of the Patent Coop	peration Treaty:		
	for which Application No	filed on	in the Pate	nt Office; and/or

(hereinafter "Application(s)")

WHEREAS, CuRNA, Inc., a corporation of the State of Delaware, having a place of business at 4400 Biscayne Boulevard, Miami, Florida 33137 (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

- 1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title, and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any said Patent(s).
- 2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said

Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefore and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date:, 2012		Jospeh Collard
STATE OF FLORIDA COUNTY OF)	SS:
On this day of, 201 me known to be the person named in a to me that he executed the same for the set forth.	and who executed the	e above instrument, and acknowledged
SEAL	Notary Public	
My commission expires		

Date: 07/23, 2012	Olga Khorkova Sherman
STATE OF FLORIDA	
COUNTY OF PALM BEACK) SS:	
known to be the person named in and who executed he executed the same for the uses and purposes the	ersonally appeared <u>Olga Khorkova Sherman</u> , to med the above instrument, and acknowledged to me that rein
PAUL BENDIG Notary Public - State of Florida My Comm. Expires Feb 6, 2016 Commission # EE 166832 Notary	y Public Can Co

My commission expires Feb 6,2014

	PATENT ASSIGNMENT	Docket Number:	SEE EXHII	BIT A
WHEREAS,	the undersigned:			
1. COLI	ARD, Joseph, 1004 Brooks Lane, Delray Bea	ch, FL 33483		
(hereinafter '	'Inventor(s)"), have invented certain new and	useful improvements	in	
	SEE EX	XHIBIT A		
\boxtimes	for which a United States Patent Application for which Provisional Application No(s). Sunited Stated Patent Office;			
\boxtimes	for which International Application No. <u>SEI</u> Receiving Office of the Patent Cooperation T		on SEE EXH	IBIT A in the U.S.
	for which Application Nofiled	oni	n the	_ Patent Office; and/or
hereinafter '	'Application(s)")			
Biscayne Bo and interest i	OPKO CuRNA, LLC, a corporation of the Staulevard, Miami, Florida 33137 (hereinafter "An and to said Application(s) and the inventions eretofore conceived, made or discovered, whet	ssignee"), is desirous disclosed therein, and	of acquiring t d in and to all	the entire right, title embodiments of the

collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

- Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title, and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any said Patent(s).
- The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

countries, or under any	international convention, agre	ement, protocol,	s) issuing in the United States, foreign or treaty, be issued in the name of the ee, its successors, legal representatives and	d
IN WITI Assignee as of the date		or(s) have execut	ed and delivered this instrument to said	
Date: Scp	<u> 7</u> 2011		Joseph Collard	
STATE OF COUNTY OF _	FLORIDA PALMI BEACH	_)) _)	SS:	
me known to be	ty of SETTIN BEC 2011, better the person named in and where the day of the discount of the dis	no executed the	ally appeared <u>Joseph Collard</u> , to above instrument, and acknowledged herein.	
SEAL		Notary Public	(1
My commissior	expires $12/20/20/3$			

Exhibit A

Target	Application No.:	Filing Date:	Attorney Docket No.:	Title:
APO A1	PCT/US2009/059457	02-Oct-2009	CURN00030	TREATMENT OF APOLIPOPROTEIN-AI RELATED DISEASES BY
APO A1	12/573,083	02-Oct-2009	CURN00030	TREATMENT OF APOLIPOPROTEIN-AI RELATED DISEASES BY
SIRT1	13/132,987	06-Jun-2011	CURN00050	TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY
SIRTI CIP	13/254,600	13-Sep-2011	CURN00060	TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY
SIRT3 Prov	61/330,427	03-May-2010	CURN00070	TREATMENT OF SIRTUIN3 (SIRT3) RELATED DISEASES BY
SIRT	PCT/US2011/021052	13-Jan-2011	CURN00070	TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY
VEGF	PCT/US2009/066455	02-Dec-2009	CURN00080	TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR
VEGF	13/132,997	15-Jun-2011	CURN00080	TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR
EPO	PCT/US2009/066659	03-Dec-2009	CURN00090	TREATMENT OF ERYTHROPOLETIN (EPO) RELATED DISEASES BY
EPO	13/133,025	15-Jun-2011	CURN00090	TREATMENT OF ERYTHROPOIETIN (EPO) RELATED DISEASES BY
TUMOR SUPPRESS	PCT/US2009/066654	03-Dec-2009	CURN00100	TREATMENT OF TUMOR SUPPRESSOR GENE RELATED DISEASES
TUMOR SUPPRESS	13/133,039	15-Jun-2011	CURN00100	TREATMENT OF TUMOR SUPPRESSOR GENE RELATED DISEASES
PAR4	61/334,933	14-May-2010	CURN00111	TREATMENT OF PAWR RELATED DISEASES BY INHIBITION OF
PCR4	PCT/US2011/036557	14-May-2011	CURN00111	TREATMENT OF PAR4 RELATED DISEASES BY INHIBITION OF
NEU4	61/390,216	06-Oct-2010	CURN00112	TREATMENT OF SIALIDASE 4 (NEU4) RELATED DISEASES BY
IDUA	61/405,758	22-Oct-2010	CURN00113	TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED
IFRD1	61/407,045	27-Oct-2010	CURN00114	TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL
NANOG	61/416,341	23-Nov-2010	CURN00115	TREATMENT OF NANOG RELATED DISEASES BY INHIBITION OF
BCL2L11	PCT/US2011/037079	19-May-2011	CURN00121	TREATMENT OF BCL2-LIKE 11 (BCL2L11) RELATED DISEASES BY
BCL2L11	61/346,252	19-May-2010	CURN00121	TREATMENT OF BCL2-LIKE 11 (BCL2L11) RELATED DISEASES BY
FXN	61/494,928	09-Jun-2011	CURN00125	TREATMENT OF FRATAXIN (FXN) RELATED DISEASES BY
RNAse	PCT/US2011/022304	25-Jan-2011	CURN00130	TREATMENT OF RNASE H1 RELATED DISEASES BY INHIBITION
RNAse	61/297,878	25-Jan-2010	CURN00130	TREATMENT OF RNASE HI RELATED DISEASES BY INHIBITION
LHX2	61/346,284	19-May-2010	CURN00131	TREATMENT OF LIM HOMEOBOX 2 (LHX2) RELATED DISEASES BY
LHX2	PCT/US2011/037080	19-May-2011	CURN00131	TREATMENT OF LIM HOMEOBOX 2 (LHX2) RELATED DISEASES BY
ATOH	61/348,656	26-May-2010	CURN00141	TREATMENT OF ATONAL HOMOLOG I (ATOHI) RELATED DISEASES
ATOH	PCT/US2011/037833	25-May-2011	CURN00141	TREATMENT OF ATONAL HOMOLOG 1 (ATOH1) RELATED

ALOX12B 61/302,188 08-Feb-2010 CUR ALOX12B PCT/US2011/023931 07-Feb-2011 CUR MSRA 61/348,650 26-May-2010 CUR MSRA PCT/US2011/037835 25-May-2010 CUR PYCR1 61/306,748 22-Feb-2010 CUR PYCR1 PCT/US2011/02582 21-Feb-2011 CUR SCN1A PCT/US2011/041664 23-Jun-2010 CUR SCN1A PCT/US2011/041664 23-Jun-2010 CUR CSF3 61/320,414 02-Apr-2010 CUR PUMA 61/363,535 12-Jul-2011 CUR BBC3 PCT/US2011/043694 12-Jul-2010 CUR FGF21 FGF21 FGF21 PCT/US2011/043694 12-Jul-2011 CUR DLG1 Prov 61/364,211 14-Jul-2010 CUR DLG PCT/US2011/043804 13-Jul-2011 CUR NKX6-1 Prov 61/364,211 14-Jul-2010 CUR NAMPT 61/375,126 19-Aug-2010 CUR	O CTIRMONTSO	DISEASES
12B PCT/US2011/023931 O7-Feb-2011 61/348,650 26-May-2010 61/306,748 22-Feb-2010 61/306,748 22-Feb-2010 7 61/357,774 23-Jun-2011 1357,774 23-Jun-2011 1357,774 23-Jun-2011 14320,414 02-Apr-2010 15 16 1/353,535 12-Jul-2010 16 1/323,525 09-Apr-2010 17 61/323,027 12-Apr-2010 18 19 14-Jul-2010 19 19 19 19 19 10 19 19 19 11 19 19 19 11 19 19		
61/348,650 61/348,650 61/348,650 61/348,650 61/306,748 61/306,748 61/306,748 22-Feb-2010 A PCT/US2011/025582 21-Feb-2011 A BCT/US2011/041664 23-Jun-2010 BCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/043694 13-Jul-2010 TG1/323,627 12-Apr-2010 TG1/323,027 12-Apr-2010 TG1/375,126 19-Aug-2010 TS-Jul-2010	+	TREATMENT OF ARACHDONATE 12-ELFOATGENASE, 12R 11RE
PCT/US2011/037835 25-May-2010		INEATMENT OF ANACHIDONATE 12-LIPOAYGENASE, 12R 1YPE
PCT/US2011/037835 25-May-2011 61/306,748 22-Feb-2010 PCT/US2011/025582 21-Feb-2011 61/357,774 23-Jun-2010 PCT/US2011/041664 23-Jun-2011 61/320,414 02-Apr-2010 PCT/US2011/030873 01-Apr-2010 61/363,535 12-Jul-2010 PCT/US2011/043694 12-Jul-2010 PCT/US2011/031665 08-Apr-2010 PCT/US2011/043804 13-Jul-2010 PCT/US2011/043804 13-Jul-2010 PCT/US2011/043804 13-Jul-2010 T 61/375,126 19-Aug-2010 T 61/375,126 25-Jan-2010	10 CURN00151	TREATMENT OF METHIONINE SULFOXIDE REDUCTASE A (MSRA)
1 61/306,748 22-Feb-2010 1 PCT/US2011/025582 21-Feb-2011 A 61/357,774 23-Jun-2010 A FCT/US2011/041664 23-Jun-2011 61/320,414 02-Apr-2011 FCT/US2011/030873 01-Apr-2011 61/363,535 12-Jul-2011 FCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2011 Prov 61/322,352 09-Apr-2011 Prov 61/322,352 13-Jul-2010 PCT/US2011/043804 13-Jul-2011 -1 Prov 61/323,027 12-Apr-2010 -1 Prov 61/323,027 12-Apr-2010 -1 Prov 61/323,027 12-Apr-2010 -1 Prov 61/323,027 25-Jan-2010	11 CURN00151	TREATMENT OF METHIONINE SULFOXIDE REDUCTASE A (MSRA)
H PCT/US2011/025582 21-Feb-2011 A BL/357,774 23-Jun-2010 A PCT/US2011/041664 23-Jun-2010 B G1/320,414 02-Apr-2010 C G1/363,535 01-Apr-2010 C G1/363,535 12-Jul-2010 C PCT/US2011/043694 12-Jul-2010 B PCT/US2011/043694 12-Jul-2011 C G1/322,352 09-Apr-2010 C G1/34,211 14-Jul-2010 C G1/364,211 14-Jul-2010 C G1/354,211 14-Jul-2010 C G1/354,211 14-Jul-2010 C G1/354,213 12-Apr-2010 C G1/354,214 13-Jul-2011 C G1/375,126 19-Aug-2010 C G1/375,126 25-Jan-2010	0 CURN00160	TREATMENT OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1)
A PCT/US2011/041664 23-Jun-2010 A (1/320,414 02-Apr-2011 B (1/320,414 02-Apr-2011 C (1/363,535 12-Jul-2011 PCT/US2011/043694 12-Jul-2011 B (1/322,352 09-Apr-2011 Prov (1/322,11 14-Jul-2011 Prov (1/364,211 14-Jul-2011 PCT/US2011/043804 13-Jul-2011 PCT/US2011/043804 13-Jul-2011 PCT/US2011/043804 13-Jul-2011 -1 Prov (1/323,027 12-Apr-2010 T (1/375,126 19-Aug-2010 25-Jan-2010	1 CURN00160	TREATMENT OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1)
A PCT/US2011/041664 23-Jun-2011 61/320,414 02-Apr-2010 PCT/US2011/030873 01-Apr-2011 61/363,535 12-Jul-2010 PCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2010 Prov 61/322,352 09-Apr-2010 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2010	0 CURN00161	TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, TYPE I, ALPHA
61/320,414 02-Apr-2010 PCT/US2011/030873 01-Apr-2011 61/363,535 12-Jul-2010 PCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2010 Prov 61/322,311 14-Jul-2010 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 -1 Prov 61/323,027 12-Apr-2010 T 61/375,126 19-Aug-2010 T 61/297,863 25-Jan-2010	1 CURN00161	TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT
PCT/US2011/030873 01-Apr-2011 61/363,535 12-Jul-2010 PCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2011 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2010 PCT/US2011/043804 13-Jul-2010 PT 61/323,027 12-Apr-2010 PT 61/375,126 19-Aug-2010 51/297,863 25-Jan-2010	0 CURN00170	TREATMENT OF COLONY-STIMULATING FACTOR 3 (CSF 3) RELATED
61/363,535 12-Jul-2010 PCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2010 Prov 61/364,211 14-Jul-2010 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 1 Prov 61/323,027 12-Apr-2010 T 61/375,126 19-Aug-2010 3 FAug-2010 25-Jan-2010	11 CURN00170	TREATMENT OF COLONY-STIMULATING FACTOR 3 (CSF 3) RELATED
PCT/US2011/043694 12-Jul-2011 61/322,352 09-Apr-2010 PCT/US2011/031665 08-Apr-2011 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 -1 Prov 61/323,027 12-Apr-2010 PT 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	CURN00171	TREATMENT OF BCL2 BINDING COMPONENT 3 (BBC3) RELATED DISEASES
61/322,352 09-Apr-2010 PCT/US2011/031665 08-Apr-2011 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 1 Prov 61/323,027 12-Apr-2010 T 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	1 CURN00171	TREATMENT OF BCL2 BINDING COMPONENT 3 (BBC3) RELATED
PCT/US2011/031665 08-Apr-2011 Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 -1 Prov 61/323,027 12-Apr-2010 *T 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	0 CURN00180	TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED
Prov 61/364,211 14-Jul-2010 PCT/US2011/043804 13-Jul-2011 5-1 Prov 61/323,027 12-Apr-2010 PT 61/375,126 19-Aug-2010 FT 61/297,863 25-Jan-2010	11 CURN00180	TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED
PCT/US2011/043804 13-Jul-2011 5-1 Prov 61/323,027 12-Apr-2010 PT 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	CURN00181	TREATMENT OF DISCS LARGE HOMOLOG 1 (DLG1) RELATED DISEASES
PT 61/323,027 12-Apr-2010 PT 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	1 CURN00181	TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES
PT 61/375,126 19-Aug-2010 61/297,863 25-Jan-2010	10 CURN00190	TREATMENT OF NK6 HOMEOBOX 1 (NKX6-1) RELATED DISEASES
61/297,863 25-Jan-2010	10 CURN00191	TREATMENT OF NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE
	0 CURN00120	TREATMENT OF PANCREATIC AND DUODENAL HOMEOBOX 1 (PDX1)
MAFA 61/297,847 25-Jan-2010 CUR	0 CURN00110	TREATMENT OF V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA
PCT/US2010/024075 12-Feb-2010	0 CURN00200	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF)
13/201,254 13-Sep-2011	11 CURN00200	TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF)
GDNF PCT/US2010/024079 12-Feb-2010 CUR	10 CURN00300	TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR
13-Sep-2011	11 CURN00300	TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR
DLK1 13/256,710 PENDING CUR	CURN00400	TREATMENT OF DELTA-LIKE I HOMOLOG (DLK1) RELATED
NRF2 13/256,720 PENDING CUR	CURN00500	TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE
61/415,307 18-Nov-2010 CUR	10 CURN00600	ANTAGONAT COMPOSITIONS AND METHODS OF USE
HNF4A 61/294,129 12-Jan-2010 CUR	0 CURN01032	TREATMENT OF HEPATOCYTE NUCLEAR FACTOR 4, ALPHA (HNF4A)
SHBG 61/293,739 11-Jan-2010 CUR	0 CURN01022	TREATMENT OF SEX HORMONE BINDING GLOBULIN (SHBG)
SHBG PCT/US2011/020768 11-Jan-2011 CUR	1 CURN01022	TREATMENT OF SEX HORMONE BINDING GLOBULIN (SHBG)
NEUROD1 61/292,508 06-Jan-2010 CUR	0 CURN01092	TREATMENT OF NEUROGENIC DIFFERENTIATION FACTOR 1 (NEUROD1)

NEUROD1	PCT/US2011/020321	06-Jan-2011	CURN01092	TREATMENT OF NEUROGENIC DIFFERENTIATION FACTOR 1 (NEUROD1)
IRF8	61/291,946	04-Jan-2010	CURN01091	TREATMENT OF INTERFERON REGULATORY FACTOR 8 (IRF8)
IFF8	PCT/US2011/020069	04-Jan-2011	CURN01091	TREATMENT OF INTERFERON REGULATORY FACTOR 8 (IRF8)
IRS2	61/291,419	31-Dec-2009	CURN01090	TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2)
IRS2	PCT/US2010/062463	30-Dec-2010	CURN01090	TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED
NRF1	61/290,549	29-Dec-2009	CURN01081	TREATMENT OF NUCLEAR RESPIRATORY FACTOR 1 (NRF1) RELATED
NRF1	PCT/US2010/062323	29-Dec-2010	CURN01081	TREATMENT OF NUCLEAR RESPIRATORY FACTOR 1 (NRF1) RELATED
p63	61/290,540	29-Dec-2009	CURN01082	TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES
P63	PCT/US2010/062326	29-Dec-2010	CURN01082	TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES
HGF	61/289,647	23-Dec-2009	CURN01072	TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED
HGF	PCT/US2010/061996	23-Dec-2010	CURN01072	TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED
UCP2	61/289,538	23-Dec-2009	CURN01080	TREATMENT OF UNCOUPLING PROTEIN 2 (UCP2) RELATED DISEASES
UCP2	PCT/US2010/062001	23-Dec-2010	CURN01080	TREATMENT OF UNCOUPLING PROTEIN 2 (UCP2) RELATED DISEASES
MBTPS1	61/286,924	16-Dec-2009	CURN01071	TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR
MBTPS1	PCT/US2010/060452	15-Dec-2010	CURN01071	TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR
HBF US	12/770,847	30-Apr-2010	CURN00700	TREATMENT OF HEMOGLOBIN (HBF/HBG) RELATED DISEASES BY
HBF	PCT/US2010/033078	30-Apr-2010	CURN00700	TREATMENT OF HEMOGLOBIN (HBF/HBG) RELATED DISEASES BY
TTP	PCT/US2010/033836	06-May-2010	CURN00800	TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY
LTMG	PCT/US2010/033908	06-May-2010	CURN00900	TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE
UTRN	61/317,350	25-Mar-2010	CURN00005	TREATMENT OF UTROPHIN (UTRN) RELATED DISEASES BY INHIBITION
FLG	61/307,654	24-Feb-2010	CURN00006	TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY INHIBITION
COL1A1	61/286,965	16-Dec-2009	CURN00007	TREATMENT OF COLLAGEN ALPHA-1(I) (COL1A1) RELATED DISEASES
COL1A2 Prov	61/286,939	16-Dec-2009	CURN00008	TREATMENT OF COLLAGEN ALPHA-2(I) (COL1A2) RELATED DISEASES
POUSF1 Prov	61/286,852	16-Dec-2009	CURN00009	TREATMENT OF POUSFI RELATED DISEASES BY INHIBITION OF
antagoNAT	61/415,858	21-Nov-2010	CURN01000	ANTAGONAT COMPOSITIONS
DMDFAMILY	PCT/US2010/034026	07-May-2010	CURN01010	TREATMENT OF DYSTROPHIN FAMILY RELATED DISEASES BY
ReprogFAC	PCT/US2010/035264	18-May-2010	CURN01011	TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY
TFE3	PCT/US2010/035842	21-May-2010	CURN01020	TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) AND INSULIN
ANTIVIRAL	PCT/US2010/036558	28-May-2010	CURN01021	TREATMENT OF ANTIVIRAL GENE RELATED DISEASES BY INHIBITION
PON1	PCT/US2010/038785	16-Jun-2010	CURN01030	TREATMENT OF PARAOXONASE 1 (PON1) RELATED DISEASES BY
COLLAGEN	PCT/US2010/038761	16-Jun-2010	CURN01031	TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION
TNFR2	PCT/US2010/039824	24-Jun-2010	CURN01040	TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2)

DsGENES	PCT/US2010/039827 24-Jun-2010	24-Jun-2010	CURN01041	TREATMENT OF DOWN SYNDROME GENE RELATED DISEASES BY
SIRT	PCT/US2010/043075 23-Jul-2010	23-Jul-2010	CURN01042	TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION
INS	PCT/US2010/044542 05-Aug-2010	05-Aug-2010	CURN01050	TREATMENT OF INSULIN GENE (INS) RELATED DISEASES BY INHIBITION
ADIPOQ	PCT/US2010/045168 11-Aug-2010	11-Aug-2010	CURN01051	TREATMENT OF ADIPONECTIN (ADIPOQ) RELATED DISEASES BY
CHIP	PCT/US2010/046102 20-Aug-2010	20-Aug-2010	CURN01052	TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP)
IQGAP	PCT/US2010/046642 25-Aug-2010	25-Aug-2010	CURN01060	TREATMENT OF 1Q MOTIF CONTAINING GTPASE ACTIVATING PROTEIN'
ABCB1	PCT/US2010/046766 26-Aug-2010	26-Aug-2010	CURN01061	TREATMENT OF ATP-BINDING CASSETTE SUB-FAMILY B MEMBER 1
FLG	PCT/US2010/050173	24-Sep-2010	CURN01062	TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION
CH	PCT/US2010/050165	24-Sep-2010	CURN01070	TREATMENT OF GROWTH HORMONE (GH) RELATED DISEASES BY
SCNxA	61/531,361	06-Sep-2011	CURN00210	TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM
		,		

RECORDED: 09/27/2012